An integrated bioinformatics analysis of the S100 in head and neck squamous cell carcinoma. 2023

Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

This study aims to evaluate the expression profile and clinical value of the S100 family in head and neck squamous cell carcinoma (HNSCC). The expression patterns, clinicopathological features, prognostic significance and underlying correlations of S100 family genes in HNSCC were determined by bioinformatics analysis with the application of several databases, including the The Cancer Genome Atlas (TCGA) and Oncomine for differential expression gene (DEG) analysis, and a series of analysis tools, including Database for Annotation, Visualization and Integrated Discovery (DAVID), cBioPortal, Kaplan-Meier Plotter, Tumor Immune Estimation Resource (TIMER) and R software packages. The results from the study demonstrated that S100A4, S100A10, and S100A13 may act as prognostic markers through overall survival (OS), disease-free survival (DFS) and tumor infiltrating immune cell enrichment and a prognostic S100 family gene model comprising S100A1-A4, S100A8, S100A10, S100A12, and S100A13 was identified. The messenger RNA (mRNA) expression of S100A1, S100A9, S100A14, and S100A7A was significantly different in HNSCC patients, together with a high mutation rate of the S100 family was found. Evaluation of clinicopathological value demonstrated the heterogeneity of S100 family functions. S100A1, S100A7, S100A8, S100A9, S100A13, S100A14, and S100A16 were observed to significantly correlate with multiple biological processes (BPs) of HNSCC, including initiation, lymph node metastasis, and lymphovascular invasion. In addition, the S100 family were significantly associated with epithelial-mesenchymal transition (EMT)-related genes. This present study demonstrated that S100 family members are implicated in the initiation, progression, metastasis and survival of HNSCC.

UI MeSH Term Description Entries

Related Publications

Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
August 2023, Oncology letters,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
August 2019, Molecular genetics & genomic medicine,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
January 2020, Frontiers in oncology,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
September 2013, Epigenetics,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
January 2020, PeerJ,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
January 2022, Disease markers,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
February 2021, Medicine,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
September 2019, International journal of clinical oncology,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
January 2023, Disease markers,
Guo Bai, and Shijing Yue, and Yuanhe You, and Jiong Zhao, and Zhuowei Tian, and Yanan Wang, and Zhiyuan Zhang, and Chi Yang
January 2021, Combinatorial chemistry & high throughput screening,
Copied contents to your clipboard!